Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
==== Leaves ==== Edible raw or cooked (depending on hardiness), the leaves can be used in many ways. They are perhaps most commonly added to clear broth-based soups, such as the Filipino dishes tinola and utan. Tender moringa leaves, finely chopped, are used as garnish for vegetable dishes and salads, such as the Kerala dish thoran. It is also used in place of or along with coriander leaves (cilantro). The leaves are also cooked and used in ways similar to spinach, and are commonly dried and crushed into a powder for soups and sauces. For long-term use and storage, moringa leaves may be dried and powdered to preserve their nutrients. Sun, shade, freeze and oven drying at 50–60 °C are all acceptable methods, albeit variable in their retention efficacy of specific micro- and macronutrients. The powder is commonly added to soups, sauces, and smoothies. Owing to its high nutritional density, moringa leaf powder is valued as a dietary supplement and may be used to enrich food products ranging from dairy, such as yogurt and cheese, to baked goods, such as bread and pastries, with acceptable palatability.
=== Computational chemistry and MacroModel === In addition to his contributions to synthetic organic chemistry, Clark Still was an early pioneer in applying computational methods to the study of organic compounds. Conformational analysis was integral to Still's study of macrocyclic stereocontrol, and there was a general need for a fast and reliable computational method for predicting an organic molecule's lowest energy conformation. In order to address the problem, Still and coworkers reported a simple Monte Carlo method for searching conformational space in 1989. In this procedure, the internal coordinates for an organic molecule were varied at random, and the energy of the lowest energy conformation was determined after structure minimization. After each iteration, the minimum energy was compared to the values obtained previously in order to locate the global minimum; Still referred to this overall process as a Monte Carlo multiple-minimum search. In an effort to make molecular modeling more accessible to practicing organic chemists, Still developed the integrated software program MacroModel in 1986 in association with Columbia University. Dr. Wayne Guida, a senior postdoctoral researcher in Still's group at the time, described the development of this software package in the following way:
Using the enediol intermediate of the reaction (which allowed solvent protons to enter the reaction from the middle instead of only from the substrate or product) and kinetic isotope effects, he measured the relative free energy of each intermediate and transition state, which allowed him to depict the first free energy profile for an enzyme-catalyzed reaction. This work was done with his long-term collaborator, John Albery. His profile showed that TIM was a "perfect" enzyme in that catalysis is limited only by the rate of diffusion. Later, Knowles applied similar methods to proline racemase, developing an elegant method to discern whether a reaction proceeds via a stepwise or concerted manner and discovering the consequences of "oversaturation", a situation in which the interconversion of unliganded forms of the enzyme limit catalysis. At Harvard, Knowles also did important work on β-lactamases and their mechanism-based inhibitors. And, he provided key insight on the stereochemistry of phosphoryl group transfer reactions, using synthetic phosphoryl groups containing 16O, 17O, and 18O isotopes. Knowles was the author of more than 250 research papers, and advised many doctoral students and post-doctoral researchers at Oxford and at Harvard, including Hagan Bayley, Stephen L. Buchwald, Athel Cornish-Bowden, Andreas Plückthun, and Ronald T. Raines.
Sources: en.wikipedia.org
Overuse injuries of the musculoskeletal system because of repetitive exercise, with young athletes (under the age of 19) particularly at risk Overtraining syndrome may lead to persistent dysfunction of a number of body systems High volumes of training with insufficient calorie intake puts athletes—particularly female ones—at risk for RED-S Aerobic exercise may not be as time-efficient as other cardiovascular training methods. For example, High-intensity interval training (HIIT) has been shown to provide similar benefits in a fraction of the time spent exercising per week. Both the health benefits and the performance benefits, or "training effect", require that the duration and the frequency of exercise both exceed a certain minimum. Most authorities suggest at least twenty minutes performed at least three times per week.
The enzyme is believed to act on the so-called "quinonoid" form of the starting dihydrobiopterin. This is in contrast to the enzyme dihydrofolate reductase, which normally acts on dihydrofolic acid but can also reduce the isomer, L-erythro-7,8-dihydrobiopterin.
== Early life and biography == Kearon was born on 18 July 1961 in Carlisle, England. He spent part of his youth in Saudi Arabia, where his father worked. After his father's death when Kearon was 19, he gave up on additional formal education and entered the workforce. His first job was working for a Member of Parliament, and he later worked for Nestlé in England, Saudi Arabia, and the United States. He owned his own public affairs consulting company before beginning his full-time service in the church. Kearon was first introduced to the church in the mid-1980s while staying with a Latter-day Saint family in Laguna, California. He has said that the family "lived a joyful existence founded on service." He met missionaries in London several years later and began learning about the church, and was baptized on Christmas Eve, 1987.
Sources: en.wikipedia.org
=== Television === Scénarios sur la drogue (2000) – directed by Guillaume Canet and Jean-Christophe Pagnac (episode "Avalanche") Nana (2001) – directed by Édouard Molinaro The Private Life of Samuel Pepys (2003) – directed by Oliver Parker Gossip Girl (2010) – directed by Mark Piznarski and starring Doillon as herself
== Interactions == Cilostazol is metabolized by CYP3A4 and CYP2C19, two isoenzymes of the cytochrome P450 system. Drugs that inhibit CYP3A4, such as itraconazole, erythromycin, ketoconazole, and diltiazem, are known to interact with cilostazol. The proton pump inhibitor omeprazole, an inhibitor of CYP2C19, increases exposure to the active metabolite of cilostazol. A single report has been made of grapefruit juice possibly increasing the effects of cilostazol; some drug information sources list this as a possible interaction. The FDA-approved labeling of cilostazol notes that grapefruit juice (which is a CYP3A4 inhibitor) increases the drug's maximum concentration by around 50%.
CLIP or Class II-associated invariant chain peptide is the part of the invariant chain (Ii) that binds to the peptide binding groove of MHC class II and remains there until the MHC receptor is fully assembled. CLIP is one of the most prevalent self peptides found in the thymic cortex of most antigen-presenting cells. The purpose of CLIP is to prevent the degradation of MHC II dimers before antigenic peptides bind, and to prevent autoimmunity. During MHC II assembly in the endoplasmic reticulum, the invariant chain polypeptide complexes with MHC II heterodimers. In a late endosome/early lysosome, cathepsin S cleaves the invariant chain, leaving CLIP bound to the MHC II complex. In the presence of antigenic peptide fragments, HLA-DM partially binds to the MHC II peptide binding groove and acts as a catalyst, releasing CLIP and allowing peptides to bind. Antigenic peptides have a high affinity for the MHC II groove, and are readily exchanged for CLIP. This occurs in most cells expressing MHC II–however, in B cells, HLA-DO functions as the accessory protein. Both HLA-DM and HLA-DO interact with each other to act as chaperone proteins and prevent the denaturing of MHC II. MHC II with bound antigen is then transported to the plasma membrane for presentation. CLIP also can affect the differentiation of T cells. MHC II + CLIP complexes are upregulated on maturing dendritic cells, which activate and differentiate T cells into Thelper (Th) and Tcytotoxic (Tc) cells. Th cells can polarize into Th1 or Th2 effector cells depending on the presence of cytokines.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.